COST-UTILITY ANALYSIS OF A NOVEL BREATH-TRIGGERED AEROSOL INHALER WHICH HAS BEEN DESIGNED TO REDUCE THE CRITICAL HANDLING ERROR OF INSUFFICIENT INSPIRATORY EFFORT
Author(s)
Forster R1, Ratcliffe A2, Lewis M2, Crossley A2, Lopez Bastida J3, Dunlop W1
1Mundipharma International Ltd, Cambridge, UK, 2Adelphi Values Ltd, Bollington, UK, 3Universidad Castilla-La Mancha, Toledo, Spain
OBJECTIVES: Up to 70–80% of patients use their inhalers incorrectly (GINA 2017). Approximately 40% of the GINA-defined Step-3+ UK population inhale ICS/LABA through dry-powder inhalers (DPIs). DPIs require forceful inhalation for optimal drug delivery. The CRITIKAL study (Price et al.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PMD80
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Respiratory-Related Disorders
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now